glp 1 mash Resmetirom and GLP-1 agonists for MASH: complementary rather than exclusive Beyond glucagon-like peptide-1: The promise

While some ingredients show limited potential, the evidence remains nuanced and should be interpreted carefully

A population-based cohort study of nearly 114,000 patients with T2D found that use of GLP-1s, compared with SGLT-2 inhibitors, was associated with a 27% higher relative risk of being diagnosed with GERD and a 55% higher relative risk of GERD-related complications

Neutral Flavor, Easy to Mix: Lightly sweet powder blends smoothly into coffee, tea, smoothies, or watersimple and convenient to enjoy anytime, no capsules or pills needed

Purpose of Review The development of long-acting incretin receptor agonists represents a significant advance in the fight against the concurrent epidemics of type 2 diabetes mellitus (T2DM) and obesity

No GP referral needed